The Marked Chart Wire · Health
Summit Therapeutics
Fda rejects Summit's lung cancer Drug application
The Food and Drug Administration has declined to approve Summit Therapeutics' treatment for lung cancer.
The Marked Chart Wire · Health
Summit Therapeutics
The Food and Drug Administration has declined to approve Summit Therapeutics' treatment for lung cancer.

Prices from Based on Thu, Nov 19 close · Opens Fri 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Biohaven
Biohaven disclosed early trial data for its antibody-drug conjugate BHV-1530. The findings showed that patients with FGFR3-altered cancers experienced shrinkage of tumors and other clinical benefits.
AstraZeneca
The FDA approved a priority review for sonesitatug vedotin, an AstraZeneca treatment targeting stomach and gastroesophageal junction tumors.
Sanofi
The European Commission granted approval for VaxRabeo to be administered to patients of any age.
Moderna
Moderna's personalized cancer vaccine, used with Merck's Keytruda, reduced the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial.
Obesity Drugs
Zealand Pharma announced the launch of its Phase 2 ZYNERGY study. The trial assesses the combined use of petrelintide and enicepatide in patients with obesity or overweight.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.